文献速递临床试验与 GCP

SPIDOL研究方案:评估鞘内注射齐考诺肽对脊髓病变所致严重难治性神经病理性疼痛的镇痛疗效

SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions.
PubMed 文献 · Trials · 2024-09-07

本研究为多中心、随机、对照、安慰剂对照、双盲临床试验,采用交叉设计,随机交替给予6个月安慰剂或鞘内齐考诺肽,总时长15个月,共纳入44例脊髓损伤后难治性神经病理性疼痛患者,主要结局为有效治疗期与安慰剂期之间疼痛强度的差异。

要点

  • 纳入脊髓损伤后神经病理性疼痛且对非侵入性治疗难治的成人患者,共44例。
  • 随机交叉设计,交替6个月安慰剂或鞘内齐考诺肽,总研究时长15个月。
  • 主要结局为所有患者有效治疗期与安慰剂期疼痛强度差异。

核心结论

  • 研究旨在确定慢性鞘内注射齐考诺肽治疗脊髓损伤神经病理性疼痛的长期(6个月)疗效。

研究设计与样本

  • 多中心、随机、对照、安慰剂对照、双盲临床试验,采用交叉设计,随机交替6个月安慰剂或鞘内齐考诺肽(ITZ) periods,总时长15个月,共纳入44例患者。
  • 研究人群为各种病因的脊髓损伤后神经病理性疼痛且对非侵入性治疗难治的患者,年龄大于18岁。
  • 干预为通过植入泵鞘内给予齐考诺肽。

主要发现

  • 主要结局为所有患者有效治疗期与安慰剂期之间疼痛强度的差异。
  • 次要结局包括持续评估疼痛强度、疼痛减轻至少30%的患者百分比、患者对疼痛缓解的满意度、严重不良事件报告、自发性和诱发性疼痛的持续时间与强度、生活质量、患者总体印象变化、每日镇痛药物摄入剂量量化、长期记忆和神经认知效应、患者身体和情绪困扰评估。

临床怎么用

  • 研究方案指出,参与本研究符合法国当前脊髓损伤神经病理性疼痛的治疗方案,所提治疗目前被视为常规实践,尽管尚无随机对照试验证据。
  • 将建立数据安全监测委员会(DSMB)进行持续安全性分析。
  • 患者将在专科疼痛中心随访,研究期后有可能继续治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Central neuropathic pain resulting from spinal cord injury is notoriously debilitating and difficult to treat with few currently available treatments. A novel molecule with intrathecal administration: Ziconotide has been approved for treatment of refractory neuropathic pain in general. It acts as a presynaptic calcium channel blocker. A pilot study has shown its potential in SCI neuropathic pain patients. OBJECTIVE: The aim of this study is to determine the long-term (6 months) efficacy of chronic intrathecal ziconotide for the treatment of neuropathic SCI pain. STUDY DESIGN: Multicenter, Randomized, Comparative, Placebo controlled, Double blind clinical trial, with a crossover of random alternated periods of 6 months (placebo or ITZ) for a total of 15 months including a total of 44 patients. STUDY POPULATION: • Patients with SCI of various etiologies exhibiting neuropathic pain refractory to non-invasive treatments. • > 18 years. INTERVENTION: Intrathecal administration of ziconotide via an implanted pump. STUDY OUTCOMES: Primary study outcome Difference in pain intensity for all patients between effective treatment and placebo periods. Secondary study outcomes 1. Continuous evaluation of pain intensity. 2. Percentage of patients with at least 30% of pain reduction. 3. Satisfaction level of the patient pain relief. 4. Declarations of serious adverse events. 5. Duration and intensity of spontaneous and provoked pain. 6. Quality of life. 7. Patient global impression of change. 8. Quantification of daily dosages of analgesic drug intake. 9. Long term memory and neurocognitive effects. 10. Assessment of the patient's physical and emotional distress. NATURE AND EXTENT OF THE BURDEN AND RISKS ASSOCIATED WITH PARTICIPATION, BENEFIT, AND GROUP RELATEDNESS: Participation in this study is in accordance with current treatment protocols for SCI neuropathic pain in France therefore it proposes a treatment that would currently be considered regular practice even though no RCT evidence is yet available. The study gives patients the advantage of directly testing versus placebo a treatment that otherwise entails significant constraints. A Data Safety Monitoring board (DSMB) will be created for continuous safety analysis. Furthermore, patients will be followed in specialized pain centers offering the possibility of continuing their treatment after the study period.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Brinzeu A, Berthiller J, Perreton N, et al. SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions. Trials. 2024. PMID: 39244617. doi:10.1186/s13063-024-08387-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。